Medicenna Therapeutics (OTCMKTS:MDNAF) Announces Quarterly Earnings Results

Medicenna Therapeutics (OTCMKTS:MDNAF – Get Free Report) posted its quarterly earnings data on Monday. The company reported ($0.03) earnings per share for the quarter, topping the consensus estimate of ($0.04) by $0.01, Zacks reports.

Medicenna Therapeutics Price Performance

Shares of Medicenna Therapeutics stock traded down $0.01 during trading hours on Tuesday, hitting $0.24. 3,400 shares of the company’s stock traded hands, compared to its average volume of 68,406. The stock has a market capitalization of $22.21 million, a price-to-earnings ratio of -1.50 and a beta of 2.09. Medicenna Therapeutics has a 12-month low of $0.23 and a 12-month high of $1.30. The company has a fifty day simple moving average of $0.30 and a 200-day simple moving average of $0.38.

Medicenna Therapeutics Company Profile

(Get Free Report)

Medicenna Therapeutics is a Canadian biotechnology company focused on developing engineered cytokine-based immunotherapies for cancer. The company’s research centers on its “Superkine” platform, which is designed to modify cytokines—proteins involved in immune signaling—to direct immune activity toward tumors. Its development programs have included MDNA11, an engineered interleukin-2 designed to stimulate cancer-fighting T cells and natural killer cells, and MDNA55, an investigational treatment targeting receptors found on certain brain tumors.

Read More

Receive News & Ratings for Medicenna Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medicenna Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.